Feasibility study to detect neural markers of psychopathology using ultra high sensitivity PET (dynamic [18F]FDG-PET)

Feasibility study to detect neural markers of psychopathology using ultra high sensitivity PET (dynamic [18F]FDG-PET) - Feasibility Brain Marker PET/CT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037854

Enrollment

Registered

2025-09-09

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This refers to cancer patients for whom [18F]FDG-PET/CT is performed for a clinical reason.

Interventions

Group 1: Patients undergoing a clinically indicated static [18F]FDG PET scan will also undergo study-related dynamic PET data acquisition. During dynamic PET data acquisition, patients will be shown s

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Justifying clinical indication for a [18F]FDG PET/CT examination • Patients with oncological diseases, predominantly lung cancer • Patients who tolerate a respective lying time of a maximum 60 minutes in the PET/CT scanner • Age =18 years • Written consent of the patient

Exclusion criteria

Exclusion criteria: • Pregnant and breastfeeding women • CNS malignancies • Psychological disorders such as clinically relevant depression, bipolar disorder etc. • Medications related to psychological disorders • Patients with claustrophobia • Patients with severely reduced general condition and/or problems/pain when lying on their back, so that extended holding time in the scanner may not be tolerated • Exclusion criteria according to StrlSchG (such as persons who are placed in an institution by court order or official order) • Limited capacity of the patient to give consent

Design outcomes

Primary

Measure	Time frame
Feasibility: Testing the feasibility of detecting neural markers during naturalistic tasks using dynamic [18F]FDG-PET (method establishment). Endpoint: establishment of a stable workflow to detect cerebral glucose metabolism by means of [18F]FDG-PET	—

Secondary

Measure	Time frame
• See differences of regional [18F]FDG kinetics during naturalistic tasks assessed by means of dynamic [18F]FDG-PET Endpoint: differences in FDG-Uptake in different brain areas during resting stage and naturalistic tasks • See differences in early dynamic PET of tumor, lymph node and other organs in the scan field of view glucose metabolism Endpoint: differences (qualitative and quantitative) in FDG-Uptake. • Collection of data necessary for the planning of further prospective studies on the definition of neuronal brain markers using PET/CT imaging Endpoint: preparation of a prospective study to detect metabolic neural markers of psychopathology during naturalistic paradigms using ultra high sensitivity PET.	—

Measure

Time frame

• See differences of regional [18F]FDG kinetics during naturalistic tasks assessed by means of dynamic [18F]FDG-PET Endpoint: differences in FDG-Uptake in different brain areas during resting stage and naturalistic tasks • See differences in early dynamic PET of tumor, lymph node and other organs in the scan field of view glucose metabolism Endpoint: differences (qualitative and quantitative) in FDG-Uptake. • Collection of data necessary for the planning of further prospective studies on the definition of neuronal brain markers using PET/CT imaging Endpoint: preparation of a prospective study to detect metabolic neural markers of psychopathology during naturalistic paradigms using ultra high sensitivity PET.

—

Countries

Germany

Contacts

Public ContactKristina Herfert

Universitätsklinikum Tübingen, Radiologie, Präklinische Bildgebung & Radiopharmazie

Kristina.Herfert@med.uni-tuebingen.de+49 7071-29-87680

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026